RT Journal Article
T1 Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data From the FANTASIIA Registry
A1 Roldan Rabadan, Inmaculada
A1 Anguita Sanchez, Manuel
A1 Marin, Francisco
A1 Angustias Quesada, Maria
A1 Camacho Siles, Jose
A1 Peinado, Rafael
A1 Bertomeu, Vicente
A1 Cequier Fillat, Angel
A1 Badimon, Lina
A1 Muniz, Javier
A1 FANTASIIA Study Researchers, 
K1 Nonvalvular atrial fibrillation
K1 Antiarrhythmic therapy
K1 Cardioversion
K1 Ablation
K1 FANTASIIA registry
K1 Rhythm-control
K1 Follow-up
K1 European-society
K1 Dronedarone
K1 Prevention
K1 Guidelines
K1 Management
K1 Countries
K1 Prognosis
K1 Mortality
AB Introduction and objectives: Recently, there have been many developments in the management of nonvalvular atrial fibrillation, antiarrhythmic and anticoagulant therapy, and nonpharmacological treatment, but these developments are not applied immediately in clinical practice. The aim of this study was to identify the overall management and antiarrhythmic therapy used in the current general population of patients with nonvalvular atrial fibrillation in Spain.Methods: A prospective, observational study of 1318 consecutive anticoagulated patients with nonvalvular atrial fibrillation, recruited between June 2013 and March 2014. We analyzed the patients' general characteristics, management, and antiarrhythmic therapy.Results: Mean age was 73.8 + 9.4 years; 42.5% were women. Atrial fibrillation was paroxysmal in 28% of the patients, permanent in 50%, persistent in 17.6%, long-standing persistent in 4.5%, and new-onset in 66 patients (5%). A rhythm control strategy was chosen in 39.4% of the patients and rate control in 60.6%. Beta-blockers were prescribed in 60.2% of the patients, digoxin in 19.5%, and calcium channel antagonists in 10.7%. The antiarrhythmic agents used were amiodarone (12.6%), flecainide (8.9%), propafenone (0.4%), sotalol (0.5%), and dronedarone (2.3%). Cardioversion had been performed previously in 41.9% of the patients, ablation in 3.4%, and atrial appendage closure in 0.2%.Conclusions: Currently, patients with nonvalvular atrial fibrillation in Spain are managed mainly with rate control, and beta-blockers in particular. They receive few antiarrhythmic agents and only a very small number of these patients undergo nonpharmacological treatments. (C) 2015 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
PB Ediciones doyma s a
SN 1885-5857
YR 2016
FD 2016-01-01
LK https://hdl.handle.net/10668/25377
UL https://hdl.handle.net/10668/25377
LA en
DS RISalud
RD Apr 5, 2025